Internal tandem duplication (ITD) in the fms-like tyrosine kinase 3 (FLT3) gene is one of the most frequent genetic alteration in acute myeloid leukemia (AML), and it is associated with worse clinical outcome. Not only the presence but also the size, localization and the rate of this variant or the presence of multiple ITDs has prognostic information. The traditional PCR based diagnostic methods cannot provide information about all of these parameters in one assay, however the application of next generation sequencing (NGS) technique can be a reliable solution for this diagnostic problem. In order to evaluate the analytical properties of an NGS-based FLT3-ITD detection assay a quality control sample was prepared from DNA of AML patients containing 19 different FLT3-ITD variants identified by NGS. The higher the total read count was in a certain sample of the NGS run, the more ITD variant types could be detected. The maximal sensitivity of FLT3-ITD detection by NGS technique was as low as 0.007% FLT3-ITD/total allele rate, however, below 0.1% rate, the reproducibility of the quantitation was poor (CV > 25%). DNA pools with several FLT3-ITDs can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation testing several different ITD sequences and rates, simultaneously.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbiotec.2019.06.305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Blood Adv
December 2024
Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)-based MRD assay (limit of detection 10-4 to 10-5), we evaluated the prognostic impact of MRD at different time points in 157 patients with FLT3-ITDpos AML who were enrolled in the German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and who were treated with a combination of intensive chemotherapy and midostaurin, followed by midostaurin maintenance. MRD negativity (MRDneg) after 2 cycles of chemotherapy (Cy2), which was observed in 111 of 142 (78%) patients, was predictive of superior 4-year rates of cumulative incidence of relapse (CIR) (4y-CIR; 26% vs 46%; P = .
View Article and Find Full Text PDFITDetect: a method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application.
BMC Bioinformatics
February 2023
Department of Genomic Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Internal tandem duplication (ITD) of the FMS-like tyrosine kinase (FLT3) gene is associated with poor clinical outcomes in patients with acute myeloid leukemia. Although recent methods for detecting FLT3-ITD from next-generation sequencing (NGS) data have replaced traditional ITD detection approaches such as conventional PCR or fragment analysis, their use in the clinical field is still limited and requires further information. Here, we introduce ITDetect, an efficient FLT3-ITD detection approach that uses NGS data.
View Article and Find Full Text PDFAn NGS based MRD evaluation from acute myeloid leukemia patients.
Int J Lab Hematol
June 2023
Sino-US Diagnostics Lab, Tianjin Enterprise Key Laboratory of AI-aided Hematopathology Diagnosis, Tianjin, China.
Article Synopsis
- Measurable residual disease (MRD) is an important factor for predicting outcomes in acute myeloid leukemia (AML), and a new next-generation sequencing (NGS) based MRD panel was developed and validated.
- The study analyzed sequencing data from 1,003 Chinese AML patients, revealing common mutations like NRAS (20.8%), NPM1 (19.4%), and FLT3-ITD (18.5%), with some differences in mutation rates compared to Caucasian patients.
- The "AML NGS-MRD hot-spot panel," which focuses on 178 key exons across 52 genes, showed high detection rates for mutations in newly diagnosed (92.5%) and post-treatment (
-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing.
Cancers (Basel)
December 2022
Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
The in-frame internal tandem duplication (ITD) of the FMS-like tyrosine kinase 3 () gene is an important negative prognostic marker in acute myeloid leukemia (AML). -ITD monitoring is essential for patients at relapse or those receiving -targeted therapies. Fragment analysis (FA) is commonly used to detect and quantify -ITDs; however, detecting low-burden -ITDs after a treatment is challenging.
View Article and Find Full Text PDFPrognostic Value of -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
J Clin Oncol
February 2023
Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Purpose: The applicability of -internal tandem duplications (-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of -ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based -ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant and multiparameter flow cytometry.
Methods: In 161 patients with de novo -ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!